Authors
Latest:
Findings of the IMMUTACE Trial in Hepatocellular CarcinomaArndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Latest:
Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in MyelomaMehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
Latest:
Considering Unmet Needs of Premenopausal Patients With Breast CancerYeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.
Latest:
About the Continued Evaluation of MK-1084 for NSCLC and MoreCarlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Latest:
Quality of Life Considered When Starting Treatment in MDSMikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.
Latest:
Whether Telehealth or In Person, Palliative Care Offer Benefits for Patients With Advanced Lung CancerJoseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.
Latest:
Evaluating Ways of Measuring MRD in Hematologic MalignanciesJerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Latest:
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare CancersThe study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.
Latest:
The Gut Microbiome and Immunotherapy: New Research Explores CBM588's Mechanism in mRCCHedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.
Latest:
High PSA Before HIFU Tied to Increased Recurrence, Treatment FailureHigh prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.
Latest:
Futibatinib Shows Promise in Breast Cancer With FGFR1 Gene AmplificationsSenthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
T-DXd Shows Promise in Treating HER2+ Breast Cancer With Brain MetsNancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.
Latest:
Biomarker Analysis Predicts Post-Osimertinib Response in EGFR+ NSCLCBenjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Latest:
Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBCIn metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.
Latest:
Increased Rates of Viral Infections in Multiple MyelomaHeinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Latest:
Spiegel Discusses the Phase 2 Study Evaluating CRG-022 in R/R LBCLJay Spiegel, MD, discusses what led to the initiation of a phase 2 study evaluating CRG-022 in patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.
Latest:
Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid CarcinomaChristine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Latest:
Comparing Tandem Stem Cell Transplant Approaches in Multiple MyelomaNicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Improving Upon Immunotherapy Advances in HCCBruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.
Latest:
Unmet Needs Remain Unfilled in the Diffuse Large B-Cell Lymphoma SpaceThomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Latest:
Colorectal Cancer Awareness Month: Overcoming Barriers to Early DetectionCharles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Latest:
I-SPY2.2: A Personalized Medicine Trial for Neoadjuvant Breast Cancer TreatmentRebecca Shatsky, MD, discusses findings from the ISPY2.2 trial presented at the 2024 ASCO Annual Meeting.
Latest:
Artificial Intelligence and Machine Learning in Cancer DetectionArtificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.
Latest:
BTK Inhibitor Therapy Can Be Stopped in CLLThe decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.
